Novartis’ Aimovig tops topiramate in migraine face-off

Novartis’ Aimovig tops topiramate in migraine face-off

Source: 
Pharmaforum
snippet: 

Novartis’ injectable migraine prevention antibody Aimovig has been shown to be more effective than topiramate – a go-to oral therapy for people with chronic migraine – in a head-to-head trial.

The HER-MES trial found that Aimovig (erenumab) was more effective at preventing migraine attacks and also better tolerated than topiramate, a generic epilepsy drug which is known to have side effects like sleepiness, dizziness, diarrhoea and nausea.